SELECT: Selecting hypoxic tumours for treatment modification
Research type
Research Study
Full title
SELECT: Selecting hypoxic tumours for treatment modification
IRAS ID
336255
Contact name
Ananya Choudhury
Contact email
Sponsor organisation
The University of Manchester
Clinicaltrials.gov Identifier
R127216, Cancer Research UK Manchester Centre; NHS002145, Sponsor study reference
Duration of Study in the UK
4 years, 1 months, 30 days
Research summary
Approximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (>25%) of patients have hypoxic tumours which respond poorly to radiotherapy. Hypoxia modification with CON (breathing O2-enriched air + oral administration of nicotinamide), significantly improves response of hypoxic tumours to radiotherapy. However, there are currently no clinically approved biomarkers to identify hypoxic tumours. Our group has developed and validated gene-expression signature-based biomarkers that identify patients with hypoxic bladder (Yang et al 2017), head and neck (Eustace et al 2013), prostate (Yang et al 2018), sarcoma (Forker et al 2023) and lung (Lane et al 2022) cancers. The bladder cancer gene-expression hypoxia signature has been shown to predict benefit from hypoxia modification using RNA from archived tumour tissue. The main purpose of this study is to demonstrate in at least two cancer types that the hypoxia biomarker predicts benefit from hypoxia modification in real-time.
REC name
West of Scotland REC 4
REC reference
24/WS/0015
Date of REC Opinion
28 Feb 2024
REC opinion
Further Information Favourable Opinion